Pharmacodynamic Assays to Facilitate Preclinical and Clinical Development of Pre-mRNA Splicing Modulatory Drug Candidates by Shi, Yihui et al.
University of Kentucky
UKnowledge
Molecular and Cellular Biochemistry Faculty
Publications Molecular and Cellular Biochemistry
8-2015
Pharmacodynamic Assays to Facilitate Preclinical
and Clinical Development of Pre-mRNA Splicing
Modulatory Drug Candidates
Yihui Shi
SRI International
Amanda S. Joyner
St. Jude Children’s Research Hospital
William Shadrick
St. Jude Children’s Research Hospital
Gustavo Palacios
St. Jude Children's Research Hospital
Chandraiah Lagisetti
SRI International
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/biochem_facpub
Part of the Biochemistry, Biophysics, and Structural Biology Commons
This Article is brought to you for free and open access by the Molecular and Cellular Biochemistry at UKnowledge. It has been accepted for inclusion in
Molecular and Cellular Biochemistry Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Shi, Yihui; Joyner, Amanda S.; Shadrick, William; Palacios, Gustavo; Lagisetti, Chandraiah; Potter, Philip M.; Sambucetti, Lidia C.;
Stamm, Stefan; and Webb, Thomas R., "Pharmacodynamic Assays to Facilitate Preclinical and Clinical Development of Pre-mRNA
Splicing Modulatory Drug Candidates" (2015). Molecular and Cellular Biochemistry Faculty Publications. 82.
https://uknowledge.uky.edu/biochem_facpub/82
Authors
Yihui Shi, Amanda S. Joyner, William Shadrick, Gustavo Palacios, Chandraiah Lagisetti, Philip M. Potter,
Lidia C. Sambucetti, Stefan Stamm, and Thomas R. Webb
Pharmacodynamic Assays to Facilitate Preclinical and Clinical Development of Pre-mRNA Splicing Modulatory
Drug Candidates
Notes/Citation Information
Published in Pharmacology Research & Perspectives, v. 3, no. 4, article e00158, p. 1-11.
© 2015 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British
Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
This is an open access article under the terms of the Creative Commons Attribution License, which permits
use, distribution and reproduction in any medium, provided the original work is properly cited.
Digital Object Identifier (DOI)
http://dx.doi.org/10.1002/prp2.158
This article is available at UKnowledge: https://uknowledge.uky.edu/biochem_facpub/82
ORIGINAL ARTICLE
Pharmacodynamic assays to facilitate preclinical and clinical
development of pre-mRNA splicing modulatory drug
candidates
Yihui Shi1, Amanda S. Joyner2, William Shadrick2, Gustavo Palacios2, Chandraiah Lagisetti1,
Philip M. Potter2, Lidia C. Sambucetti1, Stefan Stamm3 & Thomas R. Webb1
1Division of Biosciences, SRI International, Menlo Park, California 94025
2Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105
3Department of Molecular and Cellular Biochemistry, University of Kentucky, 741 South Limestone, Lexington, Kentucky 40536
Keywords
Cancer, exon-skipping reporter, in vivo
imaging, pre-mRNA splicing, spliceosome
modulators, sudemycin D6.
Correspondence
Thomas R. Webb, SRI International, 333
Ravenswood Avenue, Menlo Park,
CA 94025.
Tel: 650 859 3732;
Fax: 650 859 3153;
E-mail: thomas.webb@sri.com
Funding Information
This work was supported in part by the
National Institutes of Health (NCI
CA140474), a NIH Cancer Center Core Grant
(CA21765), and by the American Lebanese
Syrian Associated Charities (ALSAC) and St
Jude Children’s Research Hospital.
Received: 1 May 2015; Accepted: 22 May
2015
Pharma Res Per, 3(4), 2015, e00158,
doi: 10.1002/prp2.158
doi: 10.1002/prp2.158
Abstract
The spliceosome has recently emerged as a new target for cancer chemotherapy
and novel antitumor spliceosome targeted agents are under development. Here,
we describe two types of novel pharmacodynamic assays that facilitate drug
discovery and development of this intriguing class of innovative therapeutics;
the first assay is useful for preclinical optimization of small-molecule agents
that target the SF3B1 spliceosomal protein in animals, the second assay is an
ex vivo validated, gel-based assay for the measurement of drug exposure in
human leukocytes. The first assay utilizes a highly specific bioluminescent
splicing reporter, based on the skipping of exons 4–11 of a Luc-MDM2 con-
struct, which specifically yields active luciferase when treated with small-mole-
cule spliceosome modulators. We demonstrate that this reporter can be used
to monitor alternative splicing in whole cells in vitro. We describe here that
cell lines carrying the reporter can be used in vivo for the efficient pharmaco-
dynamic analysis of agents during drug optimization and development. We
also demonstrate dose- and time-dependent on-target activity of sudemycin D6
(SD6), which leads to dramatic tumor regression. The second assay relies on
the treatment of freshly drawn human blood with SD6 ex vivo treatment.
Changes in alternative splicing are determined by RT-PCR using genes previ-
ously identified in in vitro experiments. The Luc-MDM2 alternative splicing
bioluminescent reporter and the splicing changes observed in human leuko-
cytes should allow for the more facile translation of novel splicing modulators
into clinical application.
Abbreviations
BLI, bioluminescent imaging; Luc-MDM2, Luciferase construct containing MDM2
intron and exons; SD6, Sudemycin D6.
Introduction
Nearly all polymerase II transcripts undergo pre-mRNA
splicing, which is the joining of exons and the removal of
introns to form mature mRNA. The spliceosome, a large
multiprotein/RNA complex, catalyzes pre-mRNA splicing.
The spliceosome is composed of at least 170 proteins and
five snRNAs (small nuclear RNAs) (Behzadnia et al.
2007). The snRNAs are associated with proteins forming
the U1, U2, U4, U5, and U6 snRNPs.
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Exons are defined by the 50 splice site, the 30 splice
site, and the branch point. The spliceosome recognizes
these elements and then assembles, in a stepwise man-
ner, onto the nascent pre-mRNA (see Fig. 1). First, the
U1 snRNP binds to the 50 splice site thereby forming
the “early (E) complex.” This is then followed by the
binding of splicing factor 1 (SF1) to the branch point,
which in turn facilitates the binding of the U2AF factor
(U2 auxiliary factor) on the 30 splice site. Upon the sta-
bilization of U2 snRNP binding, SF1 is displaced by the
SF3 complex, which results in an interaction between
U2AF65 and SF3B1 that are components of the U2AF
and SF3B complexes, respectively. The U2 snRNP partic-
ipates in an RNA:RNA interaction with the branch
point, which leads to the recognition of the branchpoint
adenosine. Through the exchange and recruitment of
other factors, the “A complex” is transformed into the
spliceosomal “B complex” that removes an intron and
joins the exons by a trans-esterification reaction. The
intron then undergoes debranching and is subsequently
degraded (Kramer 1996).
Most pre-mRNAs contain exons that can be alternatively
spliced, that is, they can be either removed as part of
introns or included in a mature mRNA. Given the impor-
tance of alternative splicing for normal cellular function, it
is not surprising that aberrant regulation of alternative
splicing can lead to human disease. This connection to
human health is increasingly recognized and has been cov-
ered in numerous reviews (Wang et al. 2007; Kim et al.
2008; Tazi et al. 2009, 2010; Barta and Schumperli 2010;
Dhir and Buratti 2010; Hallegger et al. 2010; Raponi and
Baralle 2010; Younis et al. 2010). In most cases, changes in
alternative splicing are caused by point mutations, which
have been curated in databases (Bechtel et al. 2008a,b).
(A)
(B)
Figure 1. Schematic overview of the splicing reaction. (A) Exons are shown as boxes, introns as lines. The spliceosome recognizes the 50 and 30
splice sites and the branchpoint (indicted by the “A” in the intron). Splicing results in the joining of the exons and removal of the intron (dotted
arrow). Splicing starts with the early (E) complex formation that contains U1 snRNP recognizing the 50 splice site through RNA:RNA interaction.
The entry of U2 snRNP marks the formation of complex A that forms complex B after the entry of U4/U6/U5 snRNPs. The B complex is activated
through the exit of U4 and U1, leading to rearrangements of the U2/U5/U6 snRNPs that allows catalysis in complex C. The catalysis results in the
joining of exons and the release of the former intron as a lariat. After the splicing reaction, these snRNPs dissociate from the postspliceosomal
complex and the lariat is degraded. (B) Recognition of the branchpoint sequence through U2 snRNP in the A complex. U2 snRNA binds the RNA
surrounding the branchpoint adenosine and leads to a “bulging out” of the adenosine, which is contacted by the U2 component p14. In
addition, the U2 component SF3B1 contacts the U2AF protein, located at the 30 splice site. In this arrangement, the 50 splice site, the branchpoint
and the 30 splice site are recognized by the spliceosome. Sudemycin D6 is a promising cancer drug that binds to SF3B1, the structure is shown as
an insert.
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It is notable that deregulation of alternative splicing
is also recognized as a hallmark of cancer (Klinck et al.
2008; Venables et al. 2009; Misquitta-Ali et al. 2011;
reviewed in Kim et al. 2008; David and Manley 2010).
Recently strong evidence has accumulated that aberrant
splicing of pre-mRNA is a driver of tumorigenesis and
that modulation of this process may be a promising
novel target for cancer therapy (Bonnal et al. 2012;
Webb et al. 2013). Groundbreaking discoveries in this
area include the identification of recurrent mutations in
the SF3B1 splicing protein in numerous cancers includ-
ing myelodysplastic syndromes (Graubert et al. 2012),
chronic lymphocytic leukemia (Rossi et al. 2011; Damm
et al. 2012; Quesada et al. 2012), acute myeloid leuke-
mia (Murati et al. 2012), breast cancer (Cancer Genome
Atlas 2012), lung adenosarcoma (Imielinski et al. 2012),
and uveal melanoma (Furney et al. 2013). The selective
sensitivity of tumors to agents that target SF3B1 has
also been linked to overexpression of MYC (Hubert
et al. 2013).
Prior to the identification of recurrent mutations of
SF3B1 in cancer, two independent groups published
landmark reports demonstrating that the antitumor nat-
ural products FR901464 (Kaida et al. 2007) (FR) and
pladienolide (Kanada et al. 2007) both target SF3B1.
Thus, progress in natural product screening, target iden-
tification, medicinal chemistry applied to spliceosome
modulators, and high-throughput transcriptome
sequencing has led to a remarkable convergence of inde-
pendent research that identified a new oncology drug
target and a new class of potential small-molecule thera-
peutic agents. Subsequently we reported the design and
synthesis of FR analogs that contain only three chiral
centers (the sudemycins, including C1, D1, sudemycin
D6 [SD6], and F1) (Fan et al. 2011; Lagisetti et al.
2013), and focused our work on the lead-optimization
of the sudemycins, based on FR structure-activity rela-
tionships and a hypothetical consensus pharmacophore
model (Lagisetti et al. 2008). This work ultimately led
to SD6, which is currently in preclinical development
(Lagisetti et al. 2013). In the following we describe two
types of novel pharmacodynamic assays that facilitate
drug discovery and development of this intriguing class
of innovative therapeutics; the first assay is useful for
preclinical optimization of small-molecule agents that
target the SF3B1 spliceosomal protein in animals, the
second assay is an ex vivo validated, gel-based assay for
the measurement of drug exposure in human leukocytes.
This assay is a starting point for the development of a
pharmacodynamic assay that will require future clinical
validation in combination with pharmacokinetic data for
patients that are undergoing treatment with a drug such
as SD6.
Materials and Methods
Methods
Cell culture and drug treatment
SK-MEL-2 cells were purchased from American Type Cul-
ture Collection and cultured in minimum essential med-
ium with Earle’s salts and L-glutamine containing
1 mmol/L sodium pyruvate, 10% fetal bovine serum
(FCS) and 10 mmol/L HEPES. The pediatric rhabdomyo-
sarcoma Rh18 cells were kindly provided by Dr. P.
Houghton (Ohio State University – Nationwide Chil-
dren’s Hospital, Columbus, OH). Rh18 cells were cul-
tured in RPMI 1640 medium containing 10% FCS and
10 mmol/L Hepes. Cells are all maintained in humidified
incubator with 5% CO2 at 37°C. Sudemycins and herbox-
idiene were synthesized in the Webb lab. Pladienolide B
was purchased from EMD Millipore Corp (Billerica, MA,
U.S.A.). Compounds were dissolved in DMSO at
10 mmol/L as stock solution. DMSO concentration was
kept constant at 0.5% in all drug treatments.
Reporter construction
Plasmid containing MDM2 minigene sequence was
obtained from Dr. D. Chandler (Nationwide Children’s
Hospital) (Singh et al. 2009). The Luc-MDM2 construct
contains an MDM2 minigene sequence within the lucifer-
ase ORF in the pGL4.51 vector (Promega, Madison, WI,
U.S.A.), which contains synthetic firefly luciferase luc2
gene under the control of CMV promoter. Intron 3
through Intron 11 of the MDM2 minigene sequence is
inserted at nucleotide 477 of the luciferase ORF. A stop
codon was engineered into exon 4 of MDM2.
Transient transfection and generation of stable
cell lines
Single transfection of RL-CMV (Promega) or co-transfec-
tion of Luc-MDM2 and RL-CMV in SK-MEL-2 cells with
or without sudemycin D1 treatment was performed as
follows: On day 1, 2.5 9 106 SK-MEL-2 cells were seeded
into a 10 cm petri dish with 10 mL media and incubated
for 24 h at 37°C. On day 2, cells were transfected with
RL-CMV plasmid either alone or together with the Luc-
MDM2 construct using TransIT-2020 reagent (Mirus Bio
LLC, Madison, WI, U.S.A.) and incubated for 24 h at
37°C. On day 3, cells were harvested and plated into a
96-well plate (104 cells/well) and incubated for 24 h at
37°C. On day 4, cells were treated with indicated sudemy-
cin D1 concentrations and incubated for 4 h at 37°C.
Firefly luciferase activity was measured after the addition
of the Dual-Glo reagent (Promega), subsequently Renilla
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luciferase activity was measured after adding Stop & Glo
reagent (Promega). All luciferase activity measurements
were performed on an Envision plate reader (Perkin
Elmer, Waltham, MA, U.S.A.).
To establish a stable cell line expressing Luc-MDM2,
the SK-MEL-2 cells were first transfected with the Luc-
MDM2 plasmid and subjected to selection by changing
the media daily in the presence of G-418 (1 mg/mL) for
2 weeks. The pooled stable cells were trypsinized,
counted, and seeded sparsely (5 cells in one 100 mm petri
dish) to assure that each colony would be formed from a
monoclonal population. We selected 30 colonies and
characterized each viable clone by measuring its respon-
siveness to SD6 treatment. Briefly, cells were plated at a
density of 104 cells/well in 96-well plates (Greiner, Bio-
One, Monroe, NC, U.S.A.) for overnight culture. The fol-
lowing day, cells were treated with serial dilutions of SD6
for 4 h and One-Glo (Promega) reagents were added to
measure the luciferase activity using an Envision plate
reader. Clone YS2.5 was selected for subcloning due to its
robust growth and very large dynamic range in response
to SD6 treatment. The clones and subclones were periodi-
cally frozen down at early passages and retained for future
work.
Isolation of human lymphocytes
The blood draws were approved by the internal review
board at University of Kentucky. Blood donors underwent
overnight fasting to reduce lipids in the blood, which
facilitated later RNA isolation. The blood was added to
platelet storage bags (Blood storage, Inc., Seattle, WA,
U.S.A.) and incubated with 1 lmol/L SD6 or 1 lmol/L
DMSO as a control for up to 12 h. Lymphocytes are col-
lected in a Ficoll gradient using Histopaque columns
(Sigma-Aldrich, St. Louis, MO, U.S.A.) after 0–12 h of
treatment. RNA was extracted from the lymphocytes
using Trizol (Invitrogen, Carlsbad, CA, U.S.A.). The alter-
native splicing of different target genes was analyzed by
RT-PCR, as previously described (Convertini et al. 2014).
RT-PCR assay
Following exposure of either Rh18 cells or isolated
human lymphocytes to drugs for determined periods of
time, total RNA was prepared using an RNeasy Mini kit
(Qiagen, Valencia, CA, U.S.A.). After conversion to
cDNA using High capacity RNA-to-cDNA kit (Life Tech-
nologies, Waltham, MA, U.S.A.), PCR was performed
using specific oligonucleotides using standard protocols.
Products were analyzed using agarose gel electrophoresis
and ethidium bromide staining. The intensities of the
PCR bands were quantified using gel-densitometry. The
t-test was used to determine the significance of the
results.
Primers to test splicing changes in Rh18 cells:
MDM2_FOR: CTGGGGAGTCTTGAGGGACC; MDM2_
REV: CAGGTTGTCTAAATTCCTAGGG; Ubiquitin A_FOR:
ACCTGACCAGCAGCGTCTGATATT; Ubiquitin A_REV:
TCGCAGTTGTATTTCTGGGCAAGC.
Primers to test splicing changes in human lymphocytes:
RPp30_FOR:GAGGCCTGGCTTTTGAACTT; RPp30_REV:
CCTTGGCGTCACTTTCAGAG; DUSP11_FOR:GACATCA
AGTGCCTGATGATGA; DUSP11_REV:ATGTCCCCGGCA
CCTATT; SRRM1_FOR:GACTCTGGCTCCTCCTCCTC; S
RRM1_REV:GGACTTCTCCTCCGTCTACCA; PAPOLG_-
FOR:AAGAGATCCCATTCCCCATC; PAPOLG_REV:TGC
GTGATGTATCAATAGTTGGA; b-ACTIN_FOR:AGAGCT
ACGAGCTGCCTGAC; b-ACTIN_REV:GGATGTCCACGT
CACACTTC.
Subcutaneous xenograft model, bioluminescence
imaging, and histology
SRI International’s IACUC approved all animal studies.
Female nude mice were obtained from Taconic (Hudson,
NY, U.S.A.) and were 6–8 weeks of age at initiation of
experiments. Five million SK-MEL-2/Luc-MDM2 cells in
100 lL of 1:1 mixture of phosphate buffered saline (PBS)
and matrigel (BD Biosciences, Franklin Lakes, NJ, U.S.A.)
were subcutaneously inoculated in the flank of each mouse
under 2% isoflurane anesthesia. After the tumors had
grown to approximately 50–80 mm3 in volume, the ani-
mals were randomized into groups (3 mice per group)
according to their basal bioluminescence signal and their
tumor volume. Bioluminescence signal was obtained by
intraperitoneal injection of D-luciferin (200X luciferin stock
solution, 30 mg/mL in PBS, dose of 150 mg/kg) for
20 min. Bioluminescence imaging was performed with
IVIS spectrum (Perkin Elmer) under constant isoflurane
(2%) anesthesia. The acquired bioluminescence signals in a
region of interest (ROI) over the tumor site were recorded
as the total flux radiance (p/sec/cm3/sr) with Living Image
software (Perkin Elmer). SD6 was formulated in vehicle,
10% hydroxypropyl-beta-cyclodextrin (HPCD) in phos-
phate buffer (pH 7.4) in a stock concentration of 1.5 mg/
mL. Different doses of SD6 were administered intratumor-
ally at single doses alongside of the vehicle controls once a
day for 5 days. Mice were killed and the tumors were
excised and weighed at 21 days following the final drug
and vehicle treatment. Tumor tissues were fixed in 10%
neutral-buffered formalin, processed for paraffin embed-
ding, sectioned and hematoxylin and eosin (H&E) stained.
Sections were examined under a microscope (Leica
DM5000B, Wetzlar, Germany) equipped with a CCD video
camera and photographed.
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Results
Novel luc-MDM2 Construct and the
exon-skipping luciferase reporter assay
In order to facilitate the development of spliceosome
modulators we sought to design a reporter assay to rap-
idly report the exon-skipping activity in the context of an
intact cell. We selected the proto-oncogene MDM2 as the
basis for our reporter because its alternative splicing in
cancer is well characterized and we have previously
reported a PCR-based assay that is highly specific for
inhibitors of SF3B1 (Fan et al. 2011). MDM2 is an E3
ubiquitin ligase and chief negative regulator of the tumor
suppressor protein p53 and it is encoded by 12 exons
(Wu et al. 1993; Bartel et al. 2002). A splice variant, con-
taining only exons 3 and 12, leads to the stabilization of
p53, resulting in cell cycle arrest and/or apoptosis (Evans
et al. 2001). Our previous studies on MDM2 minigenes
(Singh et al. 2009) revealed that treatment with sudemyc-
ins induces alternative splicing such that exons 4–11 of
MDM2 are skipped (Fan et al. 2011). On the basis of
these observations, we designed an exon-skipping Luc-
MDM2 reporter (Fig. 2A); that requires skipping MDM2
exons 4, 10, and 11, inserted into the firefly luciferase
(Luc) gene, to produce full-length luciferase transcript
and bioluminescence.
We selected SK-MEL-2 cells for transfection with the
Luc-MDM2 reporter, based on this cell line’s high sensi-
tivity to SD6 (Lagisetti et al. 2013). We co-transfected a
constitutive Renilla expression vector (RL-CMV) into SK-
MEL-2 to normalize the Luc signal for transfection effi-
ciency. Co-transfection of the Luc-MDM2 with RL-CMV
in SK-MEL-2 cells produced low-luminescent background
signals in the absence of sudemycin, as the 50 end of the
luciferase sequence was predominantly spliced to MDM2
exon 4, which contains a translational stop codon
(Fig. 2A). In the presence of sudemycin a 5-fold increase
in luminescence was detected compared to the vehicle
control, which is both time and dose dependent (Fig. 2B
and C).
Development of a stable SK-MEL-2/Luc-
MDM2 cell line
In order to develop an in vivo pharmacodynamic assay
with broad applications we established an SK-MEL-2 cell
line stably expressing the same Luc-MDM2 reporter (SK-
MEL-2/Luc-MDM2) as described above. No co-expression
of RL-CMV was needed in this model as the cells were
stably transfected. We conducted dose-response and time-
course assessments of this novel stable reporter cell line
and observed increasing amounts of luciferase activity
with increasing concentrations of SD6 and exposure time
in vitro. Strong luciferase activity was obtained with 4–
8 h incubation time (Fig. 3A); however, incubation times
up to 48 h produced even higher luciferase activity (500-
fold increase from baseline at 48 h, Fig. 3B). Incubation
times of 4 h or more produced large dynamic ranges
(about 30-fold increase from baseline) in vitro, such that
(A)
(B) (C)
Figure 2. Characterization of the exon-skipping reporter. (A) The Luc-MDM2 construct contains parts of an MDM2 minigene sequence (intronic
and exonic sequences) within the luciferase ORF in the pGL4.51 vector. (B) SK-MEL-2 cells transfected with the RL-CMV plasmid alone (RL) or Luc-
MDM2 and RL-CMV plasmids (Luc + RL) and treated with either 0.5% DMSO or different concentrations of sudemycin D1 for 4 h. Dose response
curve of sudemycin D1 in Luc-MDM2/RL-CMV dual reporter assay. SK-MEL-2 cells were co-transfected with Luc-MDM2 and RL-CMV plasmids and
treated with indicated sudemycin D1 concentrations for 4 h. RLU, relative luminescence units; FF/Ren, firefly/Renilla
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4 h was chosen as the time point for further in vitro
assays. Maximum luciferase activity was obtained at
approximately 10 lmol/L at every time point. Further-
more, we confirmed the potent exon-skipping activity of
two other SF3B1 targeted agents (pladienolide B and
herboxidiene) (Kotake et al. 2007; Hasegawa et al. 2011;
Lagisetti et al. 2014) in this stable cell line (Fig. 3C).
As noted above we have previously reported an orthog-
onal RT-PCR assay for exon skipping, which can be used
to validate hits from the Luc-MDM2 screen (Fan et al.
2011). In this RT-PCR assay the maximum effects were
noted at 1–5 lmol/L (Fig. 3D).
In vivo bioluminescent pharmacodynamic
(PD) assays
We recognized an intriguing advantage of the SK-MEL-2/
Luc-MDM2 stable reporter cell line in that it can be used
for in vivo bioluminescent imaging (BLI) to rapidly and
specifically assess the in vivo PD of splicing modulatory
drugs. In conjunction with administration of the lucifer-
ase substrate D-luciferin, this enables real time non-inva-
sive measurement of alternative splicing in an animal
model. We report here that the SK-MEL-2/Luc-MDM2
stable cell line can form subcutaneous (s.c.) tumors in
immunocompromised mice, and that these tumors
respond to SD6, as measured by induction of the lucifer-
ase reporter compared to a vehicle control (Fig. 4A).
Using this model we established that an intratumoral
injection of 12 mg/kg SD6 produced a marked increase in
Luc activity, with 32-fold induction of signal observed
6 h post dosing (Fig. 4B). We further observed increasing
luciferase activity with increasing doses of SD6 by intratu-
moral injection (Fig. 4C). No adverse effects were noted
on the behavior or health of the animals during the
study.
We evaluated the effects of repeated intratumoral SD6
administration on the tumor xenografts, by dosing once
daily for 5 days. We observed that the induction of
luciferase activity decreased on the second day and after
(data not shown). We postulated that the decrease in
luciferase activity after the first dose might be due to a
decrease in the viability of the tumor cells. In order to
investigate the relationship between intratumoral SD6
administration and tumor viability we allowed tumors
to grow for three additional weeks following the final
SD6 administration and measured the weight of the
tumors. Notably, tumor weights were significantly
reduced by intratumoral treatment with SD6 in a dose-
dependent manner. Remarkably, all three SD6 treated
tumors completely regressed at the highest dose. Histo-
logical analysis revealed a high degree of necrosis at
(A) (B)
(C) (D)
Figure 3. SD6 Dose response, orthogonal RT-PCR assay, and assay validation. (A, B, and C) SK-MEL-2/Luc-MDM2 stable cells were plated at a
density of 5000/well in 96-well plates and incubated overnight at 37°C in 5% CO2. The following day, cells were treated with serial dilutions of
SD6 for 2, 4, 6, 8 (A), 48 (B) hours, or Herboxidiene or Pladienolide B (C) for 4 h, ONE-Glo reagents (Promega) were added to measure the
luciferase activity. (D) RT-PCR was performed in Rh18 cells. PCR products (in bp) are indicated by the arrows; 1604 bp represents the full-length
MDM2 transcript. 1001 and 767 bp represents alternative MDM2 splicing. Ubiquitin transcripts (165 bp) were used as a control.
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2 mg/kg, some necrosis at 0.4 mg/kg and predominantly
viable tumor cells in the vehicle control (Fig. 4D). We
are now using the SK-MEL-2/Luc-MDM2 stable reporter
cell line to efficiently optimize formulations and sched-
ules of SD6 by i.v. administration.
Potential human pharmacodynamic
biomarkers
In anticipation of future clinical trials we are also pursuing
the development of pharmacodynamic splicing biomarkers.
(A)
(C)
(B)
(D)
Figure 4. In vivo measurement of spliceosome modulation by bioluminescent imaging BLI. (A) Athymic (nude) mice were injected s.c. with SK-
MEL-2/Luc-MDM2 cells in both left and right flanks. Representative pictures of one animal treatment at different time points are shown. Either
vehicle control (V) on the left frank or 12 mg/kg SD6 (S) on the right flank were intratumorally injected into mice. Mice were imaged at 0, 3, 6,
and 24 h after injection. (B) Regions of interest (ROIs – red circles) were quantified with ImageQuant software. (C) SK-MEL-2/Luc-MDM2 cells
were injected s.c. in right flanks of nude mice. Vehicle control or three dose levels of SD6 were injected intratumorally into established tumors.
Mice were imaged 0, 3, and 6 h after injection of SD6 and ROIs were quantified, and dosed once daily for four more consecutive days. After
3 weeks, mice were sacrificed, tumors excised and weighed. P-values determined by Student’s t-test versus vehicle control are shown. * p = 0.02,
** p = 0.002, *** p = 0.001 (D) H&E stained sections of tumor tissues. Images were taken at 2009 magnification.
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In previous studies, we identified a panel of genes that
change alternative splicing patterns in Rh18, HeLa and
HEK293 cells after the treatment of sudemycin E, a close
analog of SD6 (Convertini et al. 2014). In this study, we
initiated the ex vivo treatment of human blood samples
with SD6 from volunteers using fresh samples for SD6
treatment, under standardized conditions. The effect of
SD6 ex vivo in fresh blood samples directly reports the
change in the alternative splicing patterns in primary
human cells following drug exposure.
As seen in Figure 5, we found that DUSP11, RPp30,
SRRM1, and PAPOLG genes were highly expressed in
primary human lymphocytes and exhibited alternative
splicing changes after SD6 treatment. Exon-skipping was
found in all four genes at both 6-h and 12-h time points
(Fig. 5A). We further quantified the percentage of exon
skipping of those genes in treated blood samples of four
human subjects and found that the alternative splicing
changes were statistically significant with P-values <0.01
or <0.001 (Fig. 5B).
Discussion
A general picture of the role of SF3B1 as an important
regulator of pre-mRNA 30-splice site fidelity has emerged
(Corrionero et al. 2011). The binding of U2 snRNP to
the pre-mRNA branch site is one of the most critical
steps in establishing the catalytic center of the spliceo-
some. During this binding process, an RNA-RNA duplex
is formed between the branch point sequence in the
intron and the branch point-binding region located in the
U2 RNA of the U2 snRNP. The SF3 protein complex
interacts with U2AF65, a protein that facilitates recogni-
tion of the 30 splice site (see Fig. 1). It has been shown
that the natural product FR targets SF3B1 and acts by
preventing binding of the U2 snRNA to the pre-mRNA,
thereby altering the conformation of the branch point
sequence and resulting in the generation of alternatively
spliced mRNAs (Corrionero et al. 2011; Folco et al.
2011). In addition, agents that target SF3B1, such as the
sudemycins, have been shown to alter splicing patterns
and induce exon skipping in genes such as MDM2 (Fan
et al. 2011; Lagisetti et al. 2013). The proposal that the
spliceosome is a valid target for cancer (Bonnal et al.
2012; Webb et al. 2013) has been strongly supported by
recent work (Maguire et al. 2015). Additionally, the onco-
genic function of SF3B1 mutations, which leads to the
selection of cryptic 30 -splice sites, has very recently been
elucidated (DeBoever et al. 2015). It has been observed
that the cancers that are associated with recurrent spliceo-
some mutations are uniformly heterozygous, implying
that some nonmutant and fully functional spliceosome is
required for cell viability. These observations allow for
the development of a hypothetical mechanism that can
also account for the observed exquisite sensitivity of cer-
tain tumors to SF3B1 targeted agents, whereas normal
cells are relatively resistant to drug (Lagisetti et al. 2013;
Webb et al. 2013), as cancer cells with this type of aber-
rant splicing are likely sensitive to the complete knock-
down of SF3B1 activity.
In order to discover drugs that target splicing we have
previously reported a sensitive and specific low-through-
(A) (B)
Figure 5. Alternative splicing changes from sudemycin treatment of human blood. (A) Freshly drawn human blood samples were treated with
1 lmol/L SD6 and incubated for 0–12 h. The splicing patterns were analyzed by end-point RT-PCR, as previously described (Convertini et al.
2014). The structure of the RT-PCR products is indicated schematically next to the gels. Numbers indicate the sizes of the RT-PCR products. (B)
Quantification of splicing changes in four human subjects. The shading of each bar indicates the time of drug treatment; Off-white: 0 h; Gray:
6 h; Black: 12 h. The error bars indicate standard errors between individuals, **P < 0.01, ***P < 0.001.
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put cell-based assay for alternate splicing of MDM2 in
the Rh18 cell line (Fan et al. 2011). We now describe
the development of a high-throughput, cell-based lucif-
erase reporter with multiple applications in spliceosome
modulator drug discovery and development. There have
been reports of efficient screening for modulators of
alternate pre-mRNA splicing (Arslan et al. 2013). Early
studies of the natural product splicing modulators
mostly focused on intron retention as an important
readout of splicing “inhibition” (Kaida et al. 2007; Ko-
take et al. 2007; Younis et al. 2010). However, subse-
quent groundbreaking work showed that dramatic
changes in exon-skipping are induced by spliceostatin A
and that the loss of the fidelity of the 30-splice site
selection is the fundamental change induced by this nat-
ural product derivative (Corrionero et al. 2011). Our
exon-skipping reporter system has the distinct advantage
of being able to identify splicing modulatory agents that
are relevant to cancer biology and would be missed
using intron retention-based splicing activity assays (Yo-
unis et al. 2010). We postulate that specific alternatively
spliced transcripts in exon-skipping could be identified
and serve as predictive biomarkers for splicing modula-
tor drug action in ongoing preclinical as well as in
future clinical studies.
In addition, this reporter enables efficient evaluation of
targeted activity in relevant in vivo models and will expe-
dite identification of novel spliceosome modulators and
accelerate preclinical development of anticancer agents
such as SD6. Additionally, in anticipation of future clini-
cal trials and in recognition of individual-specific alterna-
tive splicing, we have successfully investigated the use of
blood-based biomarkers that will enable the assessment of
splicing modulatory drug exposure in humans based on
alternate splicing changes that we have discovered in drug
treated human tumor cells (Convertini et al. 2014). These
animal and human pharmacodynamic assays have broad
application in drug discovery and development for splic-
ing modulatory antitumor drugs.
Spliceosome targeted drug development has been hin-
dered by the dearth of suitable targeted screening assays.
The cell-based exon-skipping luciferase reporter described
here may also have the potential to identify novel spliceo-
some modulators in vitro and also serve to bridge into
late-stage in vivo lead compound optimization. We are
currently in the process of testing the potential of this
construct as a screening tool and will report the results of
this work in the future. Thus, the Luc-MDM2 cell line
provides two unique tools for both drug discovery and
development of novel splicing modulator drug leads.
BLI has been demonstrated to be a valuable technique
for evaluation of drug efficacy (Vassileva et al. 2008) and
functional activity in noninvasive animal models (Weber
et al. 2013). Here, we extended the use of BLI to monitor
mechanism-based activity for pharmacodynamic studies
and for our future studies of formulation, scheduling,
and optimization that are needed for drug development.
The novel application of this bioluminescence-based
model offers a high signal-to-noise ratio, resulting in a
highly sensitive assay for targeted activity of splicing mod-
ulators in real time in vivo. In addition, drug combina-
tions of splicing modulators with other targeted drugs
can be explored to determine optimal doses and the
sequence of administration of drugs like SD6 in order to
maximize targeted efficacy in vivo.
Separately we have developed an ex vivo assay to
measure the drug exposure in human leukocytes using
genes that may serve as a starting point in the develop-
ment of pharmacodynamic biomarkers for future clinical
studies. The four genes that we have identified in this
study can be analyzed in order to quantify the percent-
age of exon skipping to serve as markers that can be
tested in a clinical setting using drug pharmacokinetic
data. If validated this type of pharmacodynamic marker
may be useful from the preclinical phase through all of
the clinical phases of drug development. In the future,
we will correlate the confirmed alternative splicing of
these markers to drug dose levels, to the time after
administration and to the circulating drug levels, with a
significant panel of patients receiving SD6 in a clinical
setting. Further validation and completion of the phar-
macodynamic biomarker identification will help guide
future clinical trials, as those biomarkers can be adapted
for use in screening patient samples, and could be used
to show drug effects in blood over the time coarse of
the treatment. Assays of this type will allow for the
development of a more optimal dosing regimen and
schedule thus improving patient benefit and the quality
of future clinical trials.
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